Tag: cost

COLUMBUS, Wis., July 24, 2025 (GLOBE NEWSWIRE) -- In a market update released today, Michael Eisenga, CEO of First American Properties LLC, addressed significant trends emerging in the U.S. housing sector for the month of June. Citing a confluence of weakening price trends, rising inventory, and a pullback in single-family home construction, Eisenga emphasized that the second half of 2025 may mark a structural shift in market dynamics—offering buyers more leverage than at any point in the past two years.

CALGARY, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2025 results on Thursday, July 31, 2025. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, cenovus.com.

BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the second quarter ended June 28, 2025. Key results were:

_{⁽¹⁾ Volume is measured on a standard physical case basis and is used to standardize differing package configurations delivered via direct store delivery.}

New ‘Big Beautiful Bill’ Creates a 2026 ‘Certainty Cliff’ Due to Supply Chain Rules, Interconnection Delays, and Shifting ITC Requirements, Prompting CFOs and VPs of Finance to Accelerate Project Planning.

VERO BEACH, Fla., July 24, 2025 (GLOBE NEWSWIRE) --  (July 24, 2025) – Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended June 30, 2025.

Investors can contact the law firm at no cost to learn more about recovering their losses

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx^® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.